BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15303572)

  • 1. Anti-nuclear antibody, anti-DNA, and aCL in Graves' disease patients treated with propyluracil or methimazole.
    Huang CN; Hsu TC; Chou HH; Tsay GJ
    Lupus; 2004; 13(6):450-4. PubMed ID: 15303572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
    Huang CN; Hsu TC; Chou HH; Tsay GJ
    J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil.
    Sato H; Hattori M; Fujieda M; Sugihara S; Inomata H; Hoshi M; Miyamoto S
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4270-3. PubMed ID: 11095466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antinuclear antibody positivity in pediatric patients with autoimmune thyroid disease.
    Inamo Y; Harada K
    J Rheumatol; 1997 Mar; 24(3):576-8. PubMed ID: 9058668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
    Komaki T; Sakata S; Nakamura S; Matsuda M; Kojima N; Takuno H; Miura K
    Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):627-39. PubMed ID: 2583311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease.
    Sera N; Ashizawa K; Ando T; Abe Y; Ide A; Usa T; Tominaga T; Ejima E; Yokoyama N; Eguchi K
    Thyroid; 2000 Jul; 10(7):595-9. PubMed ID: 10958312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis.
    Wall JR; Fang SL; Kuroki T; Ingbar SH; Braverman LE
    J Clin Endocrinol Metab; 1984 May; 58(5):868-72. PubMed ID: 6200492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole.
    Wada N; Mukai M; Kohno M; Notoya A; Ito T; Yoshioka N
    Endocr J; 2002 Jun; 49(3):329-34. PubMed ID: 12201217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU).
    Kubota S
    Intern Med; 2016; 55(22):3235-3237. PubMed ID: 27853063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
    Kashiwai T; Hidaka Y; Takano T; Tatsumi KI; Izumi Y; Shimaoka Y; Tada H; Takeoka K; Amino N
    Endocr J; 2003 Feb; 50(1):45-9. PubMed ID: 12733708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Differential Effects of Propylthiouracil and Methimazole as Graves' Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial.
    Wisnu W; Alwi I; Nafrialdi N; Harimurti K; Pemayun TGD; Jusman SWA; Santoso DIS; Harahap AR; Suwarto S; Subekti I
    Front Endocrinol (Lausanne); 2021; 12():796194. PubMed ID: 34987480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antithyroid drugs on the occurrence of antibodies against type 2 deiodinase (DIO2), which are involved in hyperthyroid Graves' disease influencing the therapeutic efficacy.
    Molnár I; Szentmiklósi JA; Gesztelyi R; Somogyiné-Vári É
    Clin Exp Med; 2019 May; 19(2):245-254. PubMed ID: 30610492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.
    Komiya I; Yamada T; Sato A; Kouki T; Nishimori T; Takasu N
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3540-4. PubMed ID: 11502776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid hormone autoantibodies in patients with Graves' disease: effect of anti-thyroid drug treatment.
    Ogawa T; Sakata S; Nakamura S; Takuno H; Matsui I; Sarui H; Yasuda K
    Clin Chim Acta; 1994 Aug; 228(2):113-22. PubMed ID: 7988028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.